How Do Differences in Treatment Impact Racial and Ethnic Disparities in Acute Myeloid Leukemia

摘要: Background: We previously demonstrated disparate acute myelogenous leukemia (AML) survival for black and Hispanic patients; these differences persisted despite younger ages higher prevalence of favorable cytogenetics in groups. This study determined: (i) whether there are treatment delivered to minorities, (ii) how affect outcomes AML. hypothesize that explain some proportion disparities. Methods: used California Cancer Registry data linked hospital discharge abstracts patients with AML (1998–2008). Logistic regression models estimated odds (chemotherapy and/or hematopoietic stem cell transplant) by race/ethnicity. Cox proportional hazard mortality race after adjustment treatment. Results: analyzed 11,084 records. Black was associated lower chemotherapy [OR, 0.74; 95% confidence interval (CI), 0.61–0.91]. had decreased transplant [(OR, 0.64; CI, 0.46–0.87); (OR, 0.62–0.89), respectively]. increased (HR, 1.14; 1.04–1.25) compared whites. Adjustment receipt any resulted 1.09; 1.00–1.20) patients. Conclusions: the disparity. Future disparities studies should investigate socioeconomic other characteristics. Impact: Study findings may better elucidate drivers Epidemiol Biomarkers Prev; 24(2); 344–9. ©2015 AACR . This article is featured Highlights Issue, [p. 321][1] [1]: /lookup/volpage/24/321?iss=2